Contract with Customer, Asset, after Allowance for Credit Loss
West Pharmaceutical Services Contract with Customer, Asset, after Allowance for Credit Loss increased by 29.4% to $15.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 40.3%, from $25.80M to $15.40M. Over 5 years (FY 2020 to FY 2025), Contract with Customer, Asset, after Allowance for Credit Loss shows relatively stable performance with a 1.8% CAGR.
Analysis
How to read this metric
An increase suggests higher unbilled service activity or potential delays in collection, while a decrease indicates faster cash conversion or lower unbilled revenue.
Detailed definition
This represents the net carrying amount of assets arising from contracts with customers, recognized when the entity has...
Peer comparison
Comparable to unbilled receivables or contract assets at other financial services firms and asset managers.
other_contract_with_customer_asset_netHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.10M | $12.80M | $14.60M | $14.80M | $14.80M | $18.30M | $16.30M | $19.40M | $21.40M | $19.90M | $21.50M | $19.90M | $22.60M | $42.30M | $23.30M | $25.80M | $27.90M | $27.50M | $11.90M | $15.40M |
| QoQ Change | — | +26.7% | +14.1% | +1.4% | +0.0% | +23.6% | -10.9% | +19.0% | +10.3% | -7.0% | +8.0% | -7.4% | +13.6% | +87.2% | -44.9% | +10.7% | +8.1% | -1.4% | -56.7% | +29.4% |
| YoY Change | — | — | — | — | +46.5% | +43.0% | +11.6% | +31.1% | +44.6% | +8.7% | +31.9% | +2.6% | +5.6% | +112.6% | +8.4% | +29.6% | +23.5% | -35.0% | -48.9% | -40.3% |
Contract with Customer, Asset, after Allowance for Credit Loss at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's contract with customer, asset, after allowance for credit loss?
- West Pharmaceutical Services (WST) reported contract with customer, asset, after allowance for credit loss of $15.40M in Q1 2026.
- How has West Pharmaceutical Services's contract with customer, asset, after allowance for credit loss changed year-over-year?
- West Pharmaceutical Services's contract with customer, asset, after allowance for credit loss decreased by 40.3% year-over-year, from $25.80M to $15.40M.
- What is the long-term trend for West Pharmaceutical Services's contract with customer, asset, after allowance for credit loss?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's contract with customer, asset, after allowance for credit loss has grown at a 1.8% compound annual growth rate (CAGR), from $10.90M to $11.90M.
- What does contract with customer, asset, after allowance for credit loss mean?
- The net value of services provided to customers for which payment has been earned but not yet received.